文献速递儿童青少年精神

注意缺陷多动障碍药物使用趋势:基于人群数据库的回顾性观察研究

Trends in attention-deficit hyperactivity disorder medication use: a retrospective observational study using population-based databases.
PubMed 文献 · Lancet Psychiatry · 2018-09-13

该研究利用13个国家和1个特别行政区的人群数据库,采用统一方案回顾性分析2001至2015年间3岁及以上人群ADHD药物使用情况。

要点

  • 所有国家和地区儿童及成人ADHD药物使用率均呈逐年上升趋势。
  • 哌甲酯是多数国家最常用的ADHD药物。

核心结论

  • 研究显示ADHD药物使用率随时间增加,但不同区域间存在较大差异,临床实践需遵循循证指南推荐。

研究设计与样本

  • 采用统一方案定义研究人群和参数,按国家和地区、年龄和性别分层估计ADHD药物使用的年患病率及95%CI。

主要发现

  • 哌甲酯在多数国家是最常用的ADHD药物。

临床怎么用

  • 临床实践中应始终遵循循证指南的推荐使用ADHD药物。
  • 需进一步研究描述ADHD药物短期和长期的安全性与有效性,尤其针对成人,以支持循证指南制定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The use of medications to treat attention deficit hyperactivity disorder (ADHD) has increased, but the prevalence of ADHD medication use across different world regions is not known. Our objective was to determine regional and national prevalences of ADHD medication use in children and adults, with a specific focus on time trends in ADHD medication prevalence. METHODS: We did a retrospective, observational study using population-based databases from 13 countries and one Special Administrative Region (SAR): four in Asia and Australia, two in North America, five in northern Europe, and three in western Europe. We used a common protocol approach to define study populations and parameters similarly across countries and the SAR. Study populations consisted of all individuals aged 3 years or older between Jan 1, 2001, and Dec 31, 2015 (dependent on data availability). We estimated annual prevalence of ADHD medication use with 95% CI during the study period, by country and region and stratified by age and sex. We reported annual absolute and relative percentage changes to describe time trends. FINDINGS: 154·5 million individuals were included in the study. ADHD medication use prevalence in 2010 (in children aged 3-18 years) varied between 0·27% and 6·69% in the countries and SAR assessed (0·95% in Asia and Australia, 4·48% in North America, 1·95% in northern Europe, and 0·70% in western Europe). The prevalence of ADHD medication use among children increased over time in all countries and regions, and the absolute increase per year ranged from 0·02% to 0·26%. Among adults aged 19 years or older, the prevalence of any ADHD medication use in 2010 varied between 0·003% and 1·48% (0·05% in Asia and Australia, 1·42% in North America, 0·47% in northern Europe, and 0·03% in western Europe). The absolute increase in ADHD medication use prevalence per year ranged from 0·0006% to 0·12%. Methylphenidate was the most commonly used ADHD medication in most countries. INTERPRETATION: Using a common protocol and data from 13 countries and one SAR, these results show increases over time but large variations in ADHD medication use in multiple regions. The recommendations of evidence-based guidelines need to be followed consistently in clinical practice. Further research is warranted to describe the safety and effectiveness of ADHD medication in the short and long term, and to inform evidence-based guidelines, particularly in adults. FUNDING: None.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Raman SR, Man KKC, Bahmanyar S, et al. Trends in attention-deficit hyperactivity disorder medication use: a retrospective observational study using population-based databases. Lancet Psychiatry. 2018. PMID: 30220514. doi:10.1016/S2215-0366(18)30293-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。